Bladder cancer in 2014: From the genomic frontier to immunotherapeutics

Nat Rev Urol. 2015 Feb;12(2):74-6. doi: 10.1038/nrurol.2014.369. Epub 2015 Jan 6.

Authors

Andrew T Lenis¹, Karim Chamie¹

Affiliation

¹ Department of Urology, David Geffen School of Medicine, University of California Los Angeles, 300 Stein Plaza, 3rd Floor, Los Angeles, CA 90095, USA.

PMID: 25558841
DOI: 10.1038/nrurol.2014.369

No abstract available

Publication types

Review

MeSH terms

Adjuvants, Immunologic / therapeutic use*
BCG Vaccine / therapeutic use*
Carcinoma, Transitional Cell / genetics
Carcinoma, Transitional Cell / therapy*
Chromatin Assembly and Disassembly
Cystectomy / methods
Epigenesis, Genetic
Gene Expression Regulation, Neoplastic*
Humans
Mi-2 Nucleosome Remodeling and Deacetylase Complex
Signal Transduction
Urinary Bladder Neoplasms / genetics
Urinary Bladder Neoplasms / therapy*

Substances

Adjuvants, Immunologic
BCG Vaccine
Mi-2 Nucleosome Remodeling and Deacetylase Complex